相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients
Sirirat Anutrakulchai et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
Emaad Abdel-Kahaar et al.
FRONTIERS IN GENETICS (2019)
A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation
Sandar Min et al.
PEDIATRIC TRANSPLANTATION (2018)
Lymphocyte-depleting induction therapy lowers the risk of acute rejection in African American pediatric kidney transplant recipients
Cole N. Crowson et al.
PEDIATRIC TRANSPLANTATION (2017)
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
Nuria Lloberas et al.
PHARMACOGENETICS AND GENOMICS (2017)
Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review
V. Ruan et al.
TRANSPLANTATION PROCEEDINGS (2017)
Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact
Daniel Gonzalez et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation
N. Shuker et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype
N. Pallet et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
K. A. Birdwell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks
Laure Elens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients
Julie Bloch et al.
PHARMACOGENOMICS (2014)
Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study
Si-Yang Chen et al.
CLINICAL TRANSPLANTATION (2013)
Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure
Jason Moore et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Factors Affecting the Pharmacokinetics after Living Donor Liver Transplant
Yuichi Muraki
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2012)
Dosing equation for tacrolimus using genetic variants and clinical factors
Chaitali Passey et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: Age dependency and pharmacological interaction with steroids
Jorge R. Ferraris et al.
PEDIATRIC TRANSPLANTATION (2011)
Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients
Ping Wang et al.
PHARMACOGENOMICS (2010)
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
L. Renders et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates:: Guidelines from an experimental study
V. Haufroid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
X Zhang et al.
CLINICAL TRANSPLANTATION (2005)
Genetic variability in CYP3A5 and its possible consequences
HG Xie et al.
PHARMACOGENOMICS (2004)
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation
IAM MacPhee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
分享论文
